Vigilant Biosciences Debuts the Revolutionary BeVigilant OraFusion System in the UK

Vigilant Biosciences, Inc. (“Vigilant”), an innovator and creator of solutions aimed at facilitating the early detection of oral cancer, is proud to announce the launch of its transformative product, the BeVigilant OraFusion System, in the United Kingdom.

The BeVigilant OraFusion System stands out as an innovative device in the oral cancer domain, serving as a critical tool in oral cancer detection by identifying specific salivary biomarkers and integrating intelligent software to evaluate clinical risk factors. Detecting oral cancer in its infancy, particularly during Stage 1 or Stage 2, can dramatically improve outcomes, increasing survival rates to an impressive 90%. The current survival rate for oral cancer is 50%, predominantly due to delayed detection and intervention.

Despite oral cancer often presenting early symptoms, current dental screening limitations hinder early diagnosis. Healthcare practitioners, while diligent, may find early malignancy identification challenging, occasionally defaulting to a cautious approach. Late-stage diagnoses often necessitate extensive surgery, impacting quality of life. However, technological advancements in diagnostic methods, like the BeVigilant OraFusion System, empower practitioners to enhance early detection and dramatically improve their accuracy in assessing patients.

“Our mission revolves around elevating survival outcomes in oral cancer through early detection,” expressed Bill Brodie, CEO of Vigilant Biosciences. “The introduction of the BeVigilant OraFusion System to the UK market is a manifestation of our mission, to save lives through early detection, bringing renewed hope to those impacted by this disease.”

In its ongoing battle against oral cancer, Vigilant Biosciences perpetuates its commitment to developing straightforward, accurate and economical solutions, empowering healthcare practitioners to transform lives through timely intervention. For additional information about Vigilant Biosciences and its innovative products, please visit .

Note: The BeVigilant OraFusion System is not available for sale in the U.S.

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis.
This new collaboration is another example of Blacksmith's creative deal-making with top tier partners that bring expertise to the table which helps de-risk and accelerate scientific discoveries for the development of valuable products.
Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection 1,000 mL (2 units/mL), is indicated as an anticoagulant to maintain catheter patency.
Through this agreement, RaySearch acquires full ownership of all rights to the product DrugLog for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights.
Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics. "We are very pleased to announce the Notice of Allowance for our second patent, which will enhance the long-term value of ST-62516. Saghmos continues to build its intellectual property estate."

By using this website you agree to accept Medical Device News Magazine Privacy Policy